10-K/A: Quanterix Restates Financials Due to Inventory Valuation Error, Cites Material Weakness in Controls

Quanterix Corporation has filed an amended annual report to restate its financial statements for the past three years due to an error in inventory valuation and other unrelated errors, revealing a material weakness in internal controls.

Summary

• Quanterix Corporation has amended its annual report to restate its financial statements for the fiscal years ended December 31, 2023, 2022, and 2021.
• The restatement was necessary due to an error in the capitalization of labor and overhead costs in inventory balances, which was identified while remediating a material weakness in internal controls.
• The error impacted previously reported amounts of inventory, cost of product revenue, net loss per common share, and related financial statement totals.
• In addition to the inventory error, the restatement includes adjustments to property and equipment, accrued compensation and benefits, and operating expenses.
• The company concluded that its internal control over financial reporting was not effective as of December 31, 2023, due to material weaknesses related to inventory valuation and property and equipment accounting.
• The company incurred net losses of $28.4 million, $99.6 million, and $55.5 million for the years ended December 31, 2023, 2022, and 2021, respectively.
• Total revenues were $122.4 million, $105.5 million and $110.6 million for the years ended December 31, 2023, 2022 and 2021, respectively.

Sentiment

Score: 3

Explanation: The document reveals significant issues with financial reporting and internal controls, leading to a restatement. While there are some positive developments, the overall tone is negative due to the material weaknesses and the need for ongoing remediation efforts. The company's future outlook is also uncertain, contributing to the low sentiment score.

Positives

• Total revenues increased by 16% to $122.4 million in 2023 compared to $105.5 million in 2022.
• Cost of product revenue decreased by 32% to $29.1 million in 2023 compared to $42.8 million in 2022 due to improved manufacturing processes and inventory management.
• Interest income increased by 209% to $15.8 million in 2023 due to higher interest rates on cash, cash equivalents, and marketable securities.
• The company launched Lucent Diagnostics, a brand for clinical testing services, in July 2023.
• The company completed its assay redevelopment program in the fourth quarter of 2023, launching five new Simoa Advantage PLUS assays.

Negatives

• The company identified a material weakness in internal control over financial reporting related to inventory valuation and property and equipment accounting.
• The company's net loss was $28.4 million in 2023, although this was an improvement from the $99.6 million loss in 2022.
• Instrument sales decreased by $9.3 million in 2023 due to reduced demand.
• The company expects to incur significant expenses and operating losses at least through the next 24 months.
• The company's disclosure controls and procedures were not effective as of December 31, 2023.

Risks

• Failure to remediate material weaknesses in internal control over financial reporting could result in material misstatements in financial statements.
• The restatement of financial statements may affect investor confidence and could lead to legal proceedings or regulatory inquiries.
• The company's quarterly and annual operating results and cash flows may fluctuate significantly.
• The company has incurred annual losses since its formation and may not achieve or sustain profitability.
• The company faces significant competition in the life sciences research and diagnostic markets.
• The company relies on single contract manufacturers for its Simoa HD-X and SR-X instruments.
• Cybersecurity breaches and loss of data could compromise sensitive information and expose the company to liability.
• The company may not be successful in penetrating the diagnostics market.

Future Outlook

The company expects to incur significant expenses and operating losses at least through the next 24 months as it executes its strategy for entry into translational pharma and clinical diagnostic markets.

Management Comments

• Management concluded that the Financial Statement Close Process MW and Compensation MW were remediated as of December 31, 2023.
• Management also concluded that control deficiencies existed as of December 31, 2023, and that these control deficiencies constituted material weaknesses in our internal control over financial reporting.
• Management concluded that a portion of the Inventory MW related to the valuation of our inventory, including excess and obsolescence reserves (the Inventory Valuation MW) and the Property and Equipment MW continued to exist as of December 31, 2023.

Industry Context

The restatement and identification of material weaknesses highlight the challenges faced by companies in the life sciences sector, particularly those scaling up manufacturing and commercial operations. It also underscores the importance of robust internal controls and accurate financial reporting in maintaining investor confidence.

Comparison to Industry Standards

• The restatement due to inventory valuation errors is not uncommon in the manufacturing sector, but the identification of a material weakness in internal controls is a significant concern.
• Companies like Bio-Rad Laboratories and Illumina, which also operate in the life sciences tools and diagnostics space, have faced similar challenges related to inventory management and internal controls.
• However, the scale of the restatement and the number of years affected may be considered more significant than some of the issues faced by peers.
• The company's efforts to remediate the material weaknesses and implement new software solutions are similar to actions taken by other companies in the industry to improve financial reporting accuracy.
• The company's focus on expanding into the diagnostics market is consistent with industry trends, but the regulatory hurdles and competition in this space are significant.

Related Party Transactions

• The company has a license agreement with Tufts University, where a board member receives compensation based on royalties and license payments.
• The company has a license agreement with Harvard University, where a board member is affiliated and receives a portion of payments.
• The company had a supply agreement with UltraDx, a company formed by ARCH Venture Partners, where a former board member was affiliated.

Stakeholder Impact

• Shareholders may experience a decrease in confidence due to the restatement and material weaknesses.
• Employees may be affected by the ongoing restructuring and remediation efforts.
• Customers may be concerned about the quality and reliability of the company's products and services.
• Suppliers may be affected by changes in the company's operations and supply chain.
• Creditors may be concerned about the company's financial stability and ability to repay debts.

Next Steps

• The company will continue to implement its remediation plan to address the material weaknesses in internal control over financial reporting.
• The company will continue to evaluate, enhance, and add personnel in the finance organization.
• The company will continue to provide trainings on a regular basis related to internal control over financial reporting for all control owners.
• The company will continue to evaluate alternatives for the leased office and laboratory facilities that are not being used.

Key Dates

Keywords

restatement, inventory valuation, material weakness, internal control, financial reporting, Simoa technology, diagnostics, revenue, net loss, operating expenses